<DOC>
	<DOCNO>NCT02388490</DOCNO>
	<brief_summary>This open-label , non-randomized , multi-center , phase II trial brentuximab vedotin evaluate ORR primarily patient EBV- CD30-positive lymphoma .</brief_summary>
	<brief_title>Brentuximab Vedotin Patients With Relapsed Refractory EBV-and CD30-positive Lymphomas</brief_title>
	<detailed_description>This open-label , non-randomized , multi-center , phase II trial brentuximab vedotin evaluate ORR primarily patient EBV- CD30-positive lymphoma . The ORR evaluate base revise Cheson 's criterion modify SWAT criterion case cutaneous EBV- CD30-positive lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients relapse refractory EBV CD30positive lymphomas 2 . Age ≥ 18 year 3 . ECOG performance status 02 4 . At least one measurable lesion base revise Cheson 's modify SWAT criterion 5 . Provision archival tumor tissue ( 4 μm thickness x 5 unstained slide ) blood sample 6 . Voluntary write informed consent must give performance studyrelated procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . 7 . Female patient either postmenopausal least 1 year screen visit surgically sterile childbearing potential , agree practice 2 effective method contraception , time , time signing inform consent 6 month last dose study drug , agree completely abstain heterosexual intercourse . 8 . Male patient , even surgically sterilize , ( i.e. , status post vasectomy ) agree practice effective barrier contraception entire study period 6 month last dose study drug , agree completely abstain heterosexual intercourse . 9 . Adequate hematologic function : absolute neutrophil count ( ANC ) ≥1,500/µL , platelet count ≥ 75,000/µL , hemoglobin ≥8.0 g/dL unless know hematologic tumor marrow involvement ( ANC ≥ 1,000/µL platelet count ≥ 50,000/µL know bone marrow involvement ) 10 . Adequate liver function : total bilirubin &lt; 1.5 x upper limit normal ( ULN ) unless elevation know due Gilbert syndrome ALT AST &lt; 3 x ULN ( AST AST &lt; 5 x ULN elevation reasonably ascribe presence hematologic tumor liver ) 11 . Adequate renal function : serum creatinine &lt; 2.0 mg/dL and/or creatinine clearance calculate creatinine clearance &gt; 40 mL/minute . 12 . Expected survival &gt; 3 month 1 . Female patient lactate breastfeed positive serum pregnancy test 2 . Any serious medical psychiatric illness 3 . Known cerebral meningeal involvement ( EBV CD30positive lymphoma etiology ) , include sign symptom PML 4 . Symptomatic neurologic disease compromise normal activity require medication 5 . Any sensory motor peripheral neuropathy great equal Grade 2 6 . Known history myocardial infarction within 1 year , NYHA class III/IV heart failure , uncontrolled cardiovascular condition include cardiac arrhythmia , congestive heart failure ( CHF ) , angina , electrocardiographic evidence acute ischemia active conduction system abnormality . Recent evidence ( within 6 month first dose study drug ) leftventricular ejection fraction &lt; 50 % . 7 . Any active systemic viral , bacterial , fungal infection within 2 week prior first study drug dose 8 . Any prior chemotherapy and/or investigational agent within least 5 halflives last dose 9 . Prior stem cell transplantation within 100 day radioimmunotherapy within 8 week 10 . Prior exposure CD30targeted agent 11 . Known hypersensitivity recombinant protein , murine protein , excipient contain drug formulation brentuximab vedotin 12 . Known human immunodeficiency virus ( HIV ) positive 13 . Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection 14 . Another malignancy within 3 year first dose previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Brentuximabvedotin</keyword>
	<keyword>EBV</keyword>
	<keyword>Lymphoma</keyword>
</DOC>